We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00774761
Recruitment Status : Completed
First Posted : October 17, 2008
Last Update Posted : May 20, 2013
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the systemic exposure and pharmacodynamics of two doses of nebulized fluticasone/formoterol combination as compared to the monocomponents.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: fluticasone propionate/formoterol fumarate Drug: fluticasone propionate Drug: formoterol fumarate Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Multiple-Dose,Double-Blind,Crossover Trial to Assess the Systemic Exposure of Fluticasone Propionate (FP)/Formoterol Fumarate (FF) Fixed-Dose Combination in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Study Start Date : November 2008
Primary Completion Date : April 2009
Study Completion Date : May 2009

Arm Intervention/treatment
Experimental: 1 Drug: fluticasone propionate/formoterol fumarate
inhalation suspension
Experimental: 2 Drug: fluticasone propionate/formoterol fumarate
inhalation suspension
Active Comparator: 3 Drug: fluticasone propionate
inhalation suspension
Active Comparator: 4 Drug: fluticasone propionate
inhalation suspension
Active Comparator: 5 Drug: formoterol fumarate
inhalation solution

Primary Outcome Measures :
  1. Plasma AUC(0-t) after 1 week of dosing [ Time Frame: PK sampling over 24 hrs ]

Secondary Outcome Measures :
  1. FEV1 [ Time Frame: pre-dose and 2 hrs post-dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to understand the requirements of the study and provide consent
  • Medical diagnosis of COPD
  • A current or prior history of at least 10-pack years of cigarette smoking
  • Female of child-bearing potential to use adequate birth control

Exclusion Criteria:

  • Diagnosis of asthma
  • Other significant disease than COPD
  • Has donated a unit of blood within 30 days of study, or intends to donate
  • QTc greater than 0.460 seconds
  • Subjects who had radiation or chemotherapy in the previous 12 months
  • Subjects who had lung resection
  • History of illegal drug abuse or alcohol abuse within the past 5 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00774761

United States, California
Investigative Site
San Diego, California, United States, 92120
United States, Florida
Investigative Site
Panama City, Florida, United States, 32405
United States, Kentucky
Investigative Site
Madisonville, Kentucky, United States, 42431
United States, Louisiana
Investigative Site
Sunset, Louisiana, United States, 70584
United States, North Carolina
Investigative Site
Charlotte, North Carolina, United States, 28207
United States, Oregon
Investigative Site
Medford, Oregon, United States, 97504
United States, South Carolina
Investigative Site
Greenville, South Carolina, United States, 29615
Investigative Site
Spartanburg, South Carolina, United States, 29303
Investigative Site
Union, South Carolina, United States, 29379
United States, Texas
Investigative Site
San Antonio, Texas, United States, 78205
United States, Washington
Investigative Site
Spokane, Washington, United States, 99207
Investigative Site
Tacoma, Washington, United States, 98405
Sponsors and Collaborators

Responsible Party: Dey
ClinicalTrials.gov Identifier: NCT00774761     History of Changes
Other Study ID Numbers: 191-087
First Posted: October 17, 2008    Key Record Dates
Last Update Posted: May 20, 2013
Last Verified: May 2013

Keywords provided by Dey:

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Formoterol Fumarate
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action